TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06490757

Intervention type: DRUG
Group type: OTHER
Intervention: Baricitinib
Description: An ancillary study will be performed in a subgroup of 12 patients to assess the variation of the results of PET-CT with 18FDG from baseline to 3 months. The variation of tumor features assessed by PET-CT with 18FDG after three months of treatment, will be assessed. The median value of the SUV max and tumor to non-tumor ratio of the SUV max value for each HCA lesion between the PET CT with 18FDG performed at baseline and after 3 months of treatment will be assessed.
Study: NCT05527366

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vagus stimulation
Description: The Vagus Stimulation Group received auricular vagus stimulation for a total of 15 sessions of 25 minutes 5 days a week. The patients were applied with vagustim device consisting of TENS device with electrodes placed bilaterally in the outer ear with headphones that can be selected according to ear size. During the application, the gel was used to avoid causing any damage and to ensure conductivity. It is placed so that tragus and konkaya are facing. The pulse duration of the TENS device is less than 500 microseconds, the frequency is 10 Herzt, the module was applied in TENS mode and in the form of a biphasic asymmetric wave.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consevative treatment
Description: A total of 15 sessions 5 days a week, 20 minutes of hotpack, 20 minutes of TENS, 5 minutes of 1,3 watt/cm2 ultrasound consisting of a total of 25 minutes of treatment was applied to the neck area.
Study: NCT05021510

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simultaneous Cervical Traction & Neural Mobilization
Description: Simultaneously Mechanical Cervical traction with Neural Mobilization of the upper limb for 3 times a week, 45 minutes per day for 4 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: consecutive Cervical Traction & Neural Mobilization
Description: consecutive Mechanical Cervical traction with Neural Mobilization of the upper limb for 3 times a week, 45 minutes per day for 4 weeks
Study: NCT05055102

Intervention type: OTHER
Intervention: Data collection
Description: demographics co-morbidities risk factors operative, hospital and vascular follow-up data
Study: NCT00696358

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 308nm excimer lamp
Description: 50 mJ/cm² below the MED (minimal erythemal dose) and progressive increase Twice a week for 12 weeks

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 308nm excimer laser
Description: 50 mJ/cm² below the MED (minimal erythemal dose) and progressive increase Twice a week for 12 weeks (same doses will be used between the 2 arms)
Study: NCT05966857

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable: Smartwatch
Description: The SAMSUNGTM Galaxy Watch5 Smartwatch, is a new generation of smartwatches, features an innovative 3-in-1 BioActive sensor, which uses a chip to capture optical and read cardiac electrical current, allowing to carry out high-quality real-time single-lead electrocardiogram. Despite the more compact design, there is no decrease in accuracy. These signals are then processed by the device's algorithms and can be sent to a trained professional for evaluation immediately after the measurement, facilitating the monitoring and diagnosis of arrhythmias.
Study: NCT05816330

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: L9LS (VRC-MALMAB0114-00-AB)
Description: Administered one time via subcutaneous route.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Administered one time via subcutaneous route.
Study: NCT06169774

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational video
Description: Watch the 17-minute educational video as many times as needed within a 12-month period.
Study: NCT06009523

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: 1 stimulation per day during 15 days.
Study: NCT03275974

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Carbon C 11 Glutamine
Description: Given by IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluorine F 18 L-glutamate Derivative BAY94-9392
Description: Given by IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Draw
Description: Undergo venous blood draws
Study: NCT05234736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBL-514
Description: CBL-514 800 mg (unit dose: 2.0 mg/cm\^2)
Study: NCT04821609

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: The resistance training will be for arms and legs, self-loading type, and external weights.
Study: NCT06173037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC88
Description: 2.0 mg/kg Q3W IV
Study: NCT05903105

Intervention type: OTHER
Intervention: Questionnaires
Description: Patients fill in a questionnaire
Study: NCT04929392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Biopsy
Description: Undergo endoscopic biopsy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo EBRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib Mesylate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: Undergo surgical resection
Study: NCT05677256

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nOPV2
Description: Vaccination

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: nOPV2
Description: Vaccination
Study: NCT06098339

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens A (fanfilcon A)
Description: Daily wear for one month

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens A (fanfilcon A)
Description: Daily wear for one month

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens B (lotrafilcon B)
Description: Daily wear for one month

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens B (lotrafilcon B)
Description: Daily wear for one month
Study: NCT05597501

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: manual-based group interventions
Description: weekly group interventions (90min) following manuals of either CBT, integrative therapy or existential analysis\&logotherapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: manual-based group interventions
Description: weekly group interventions (90min) following manuals of either CBT, integrative therapy or existential analysis\&logotherapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: manual-based group interventions
Description: weekly group interventions (90min) following manuals of either CBT, integrative therapy or existential analysis\&logotherapy
Study: NCT05228899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zofin
Description: 1mL of Zofin will be administered intravenously, containing 2-5 x 10\^11 particles/mL. Zofin will be diluted in 100 mL of sterile saline.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1mL of Placebo (normal saline) will be diluted in 100 mL of sterile saline and administered intravenously.
Study: NCT05095272

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HMPBS02-Pv
Description: The blood-stage P. vivax master cell bank HMPBS02-Pv was also produced using blood collected from a consenting patient with naturally acquired malaria infection. The malaria infection was confirmed to be P. vivax by species-specific PCR at Pathology Queensland (accredited by the Australian National Association of Testing Authorities) and further confirmed by deep sequencing at the Sanger Institute. The clinical response to antimalarial chemotherapy was also demonstrated with this donor, who was successfully cured with artemether/lumefantrine.
Study: NCT05681325

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: green tea
Description: It will be given 2 cups / day for 30 days. To prepare each cup, a tea pack will be immersed into a cup of hot water.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: matcha tea
Description: It will be given 2 cups / day for 30 days. To prepare each cup, a tea pack will be immersed into a cup of hot water.
Study: NCT06341608

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth for opioid use disorder treatment delivery
Description: A multi-component patient and provider facing strategy to be designed in Aim 2. Components will likely include 1) a user-friendly telehealth platform for performing all medication induction and maintenance visits, 2) integrated case management, 3) text message scheduling reminders, 4) mailed saliva drug screening tests
Study: NCT05122390

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contraction Coper
Description: Digital application built on the Birth without fear method, based on four different tools to be used during labour. Breathing, relaxation, voice and mind.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Contraction Coper
Description: Digital application built on the Birth without fear method, based on four different tools to be used during labour. Breathing, relaxation, voice and mind.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Contraction Coper Plus
Description: Digital application built on the Birth without fear method, based on four different tools to be used during labour. Breathing, relaxation, voice and mind. Clinical guidance from a midwife during two different occasions is added to the group.
Study: NCT05592795

Intervention type: OTHER
Intervention: Whether ERCP or EST is carried out
Description: This project systematically studies the physiological characteristics of biliary microecology in normal people, and explores the impact of ERCP and EST duodenal papillary incision on biliary microecology.

Intervention type: OTHER
Intervention: Whether ERCP or EST is carried out
Description: This project systematically studies the physiological characteristics of biliary microecology in normal people, and explores the impact of ERCP and EST duodenal papillary incision on biliary microecology.
Study: NCT05097846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group1 Vonoprazan Fumarate + amoxicillin + doxycycline
Description: Vonoprazan Fumarate + amoxicillin + doxycycline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group2 Vonoprazan Fumarate + furazolidone + doxycycline
Description: Vonoprazan Fumarate + furazolidone + doxycycline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group3 esomeprazole + colloidal bismuth tartrate + amoxicillin + doxycycline
Description: esomeprazole + colloidal bismuth tartrate + amoxicillin + doxycycline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group4 esomeprazole + colloidal bismuth tartrate + furazolidone + doxycycline
Description: esomeprazole + colloidal bismuth tartrate + furazolidone + doxycycline
Study: NCT05165342

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Rexon-eye
Description: a technique in which low-intensity, high-frequency (a spectrum of frequencies ranging from 4 MHz to 64 MHz) electric currents are administered to a biological tissue through contact electrodes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rexon-eye
Description: a technique in which low-intensity, high-frequency (a spectrum of frequencies ranging from 4 MHz to 64 MHz) electric currents are administered to a biological tissue through contact electrodes
Study: NCT05950893

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pressure support level
Description: Baseline ventilators were set by the principle of keeping VT/PBW at 6-8ml/kg and RR at 20-30 breaths/min and the decision of the responsible ICU physician. After then the fraction of inspired oxygen (FiO2), positive expiratory end pressure (PEEP), trigger sensitivity, and cycle-off criteria remain unchanged. Downward PS level titration was performed from 20 cmH2O to 2 cmH2O at a 2cm H2O interval. Every PS level was maintained for 20 minutes and then three end-inspiratory holdings (2-3seconds) and three end-expiratory holdings were performed. To avoid additional injury to the lung and diaphragm, the airway peak pressure (Ppeak) was limited to 30cmH2O.Inspiratory effort is measured as pressure generated by inspiratory muscles using esophageal pressure monitoring.
Study: NCT05750329

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: assisted liver transplantation combined with two-stage hepatectomy
Description: Stage 1 Surgery: Left Hepatectomy, Left Lateral Graft Implantation, Portal Shunt to Graft Intermediate stage: continuous monitoring of liver function indexes and liver transplant donor volume after the first stage of surgery. Until the graft size reaches 0.8% of body weight (GBWR), or 35%-45% of the standard liver volume.~Stage 2 Surgery: Residual Right Hepatectomy
Study: NCT06412627

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 4°C frozen normal saline gauze
Description: Soak two 4x4 gauze pads in 15 ml of normal saline, refrigerate at 4°C, and then apply in the oral cavity for 15 minutes before removal.
Study: NCT05858138

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Jing-Si Herbal Tea
Description: patient will receive twice in a day for 24 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Jing-Si Herbal Tea
Description: Placebo Jing-Si Herbal Tea
Study: NCT06451120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP) Injections
Description: Bloods will be drawn prior to the PRP injection, and repeated at 2 weeks, 12 weeks, possibly 14 weeks for crossover patients follow up visits. Under aseptic technique with a surgical drape/curtain in place to block the study subject's view of the knee. Syringes will be covered with aluminum foil and subjects will have a cover over their eyes, so that neither subjects nor the clinical investigator will know if the injection delivered is PRP injection or a normal saline injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP) Injections
Description: Bloods will be drawn prior to the PRP injection, and repeated at 2 weeks, 12 weeks, possibly 14 weeks for crossover patients follow up visits. Under aseptic technique with a surgical drape/curtain in place to block the study subject's view of the knee. Syringes will be covered with aluminum foil and subjects will have a cover over their eyes, so that neither subjects nor the clinical investigator will know if the injection delivered is PRP injection or a normal saline injection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Centrifuge
Description: The Eppendorf Centrifuge is used to make the PRP. In our opinion, the centrifuge is a nonsignificant risk device. The centrifuge, sterile vials for blood collection and PRP injection syringes do not present a potential risk for serious health, safety or welfare of a subject. It is not needed to support or sustain human life. It is not of substantial importance in diagnosis, curing, mitigating or treating disease for the health, safety and welfare of the patients. There are no potential for serious risk to the health, safety or welfare of a subject.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Centrifuge
Description: The Eppendorf Centrifuge is used to make the PRP. In our opinion, the centrifuge is a nonsignificant risk device. The centrifuge, sterile vials for blood collection and PRP injection syringes do not present a potential risk for serious health, safety or welfare of a subject. It is not needed to support or sustain human life. It is not of substantial importance in diagnosis, curing, mitigating or treating disease for the health, safety and welfare of the patients. There are no potential for serious risk to the health, safety or welfare of a subject.
Study: NCT05886400

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SCAT6
Description: The SCAT6 is a standardized assessment tool to diagnose a concussion. This tool will be used for the experiment utilizing the 6th edition to recreate the methods used in an athletic situation. The SCAT6 is broken down into multiple subtests to focus on specific aspects of a person's wellbeing that could be affected by a possible concussion. The assessments are created to measure an athlete's subjectively experienced symptoms, cognitive functioning and balance and postural stability (mBESS).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: SCAT6
Description: The SCAT6 is a standardized assessment tool to diagnose a concussion. This tool will be used for the experiment utilizing the 6th edition to recreate the methods used in an athletic situation. The SCAT6 is broken down into multiple subtests to focus on specific aspects of a person's wellbeing that could be affected by a possible concussion. The assessments are created to measure an athlete's subjectively experienced symptoms, cognitive functioning and balance and postural stability (mBESS).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual/ Auditory Distraction
Description: The purpose of this study is to examine the effect of environmental distractions on one's ability to complete the SCAT6. The environmental distractions will be visual and auditory by playing a sports event or sports clips during the completion of the assessment. The goal of this is to simulate the distraction of a sideline like a SCAT6 is typically used within athletic training.
Study: NCT04894201

Intervention type: RADIATION
Intervention: Dental Panoramic Radiographs
Description: Exposure to dental panoramic radiographs
Study: NCT05389566

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantative Sensory Testing
Description: Evaluation of small fiber neuropathy

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantative Sensory Testing
Description: Evaluation of small fiber neuropathy

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantative Sensory Testing
Description: Evaluation of small fiber neuropathy

Intervention type: DIAGNOSTIC_TEST
Intervention: NCStat-DPN-Check
Description: Evaluation of large fiber neuropathy

Intervention type: DIAGNOSTIC_TEST
Intervention: NCStat-DPN-Check
Description: Evaluation of large fiber neuropathy

Intervention type: DIAGNOSTIC_TEST
Intervention: NCStat-DPN-Check
Description: Evaluation of large fiber neuropathy

Intervention type: DIAGNOSTIC_TEST
Intervention: Composite Autonomic Symptom Score 31
Description: Evaluation of autonomic neuropathy

Intervention type: DIAGNOSTIC_TEST
Intervention: Composite Autonomic Symptom Score 31
Description: Evaluation of autonomic neuropathy
Study: NCT05072925

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco products
Description: Products will be used under defined (10 puffs, 30 seconds apart) and ad libitum puffing conditions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco products
Description: Products will be used under defined (10 puffs, 30 seconds apart) and ad libitum puffing conditions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco products
Description: Products will be used under defined (10 puffs, 30 seconds apart) and ad libitum puffing conditions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco products
Description: Products will be used under defined (10 puffs, 30 seconds apart) and ad libitum puffing conditions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco products
Description: Products will be used under defined (10 puffs, 30 seconds apart) and ad libitum puffing conditions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco products
Description: Products will be used under defined (10 puffs, 30 seconds apart) and ad libitum puffing conditions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tobacco products
Description: Products will be used under defined (10 puffs, 30 seconds apart) and ad libitum puffing conditions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tobacco products
Description: Products will be used under defined (10 puffs, 30 seconds apart) and ad libitum puffing conditions
Study: NCT06296836

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Continuation of home metformin
Study: NCT05933759

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedical coaching
Description: Individual telemedical coaching delivered by a nutritional consultant

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low-Insulin-Method
Description: Lifestyle intervention with education via the Low-Insulin-App, low-carb diet, self-monitoring of weight and steps

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-Insulin-Method
Description: Lifestyle intervention with education via the Low-Insulin-App, low-carb diet, self-monitoring of weight and steps
Study: NCT05388500

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel + Trastuzumab
Description: Regarding neoadjuvant treatment :~- 9 to 12 weeks of neoadjuvant treatment Trastuzumab IV (8mg/kg loading dose followed by 6 mg/kg maintenance dose) or SubCutaneous (SC) (600mg fixed dose) every 3 weeks + weekly Paclitaxel IV : 80 to 90 mg/m2~Regarding adjuvant treatment patients will receive one of the following anti-HER2 therapy following the current standard to complete 1 year of anti-HER2 therapy in total :~* in case of pCR : patient will receive trastuzumab~* in case of non pCR : patients will receive trastuzumab emtansine (T-DM1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Regarding neoadjuvant treatment :~- 9 to 12 weeks of neoadjuvant treatment Trastuzumab IV (8mg/kg loading dose followed by 6 mg/kg maintenance dose) or SC (600mg fixed dose) every 3 weeks~Regarding adjuvant treatment patients will receive one of the following anti-HER2 therapy following the current standard to complete 1 year of anti-HER2 therapy in total :~* in case of pCR : patient will receive trastuzumab~* in case of non pCR : patients will receive trastuzumab emtansine (T-DM1)
Study: NCT05323461

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTV01C
Description: intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTV01C
Description: intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTV01E
Description: intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTV01E
Description: intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sinopharm inactivated COVID-19 vaccine
Description: intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comirnaty
Description: intramuscular injection